Clinical trial / 2018
TA-65 supplementation improved HDL-C, LDL/HDL ratio, BMI, waist circumference, and TNF-alpha in patients with metabolic syndrome.
A double-blind, randomized crossover trial evaluated the effects of 16 mg daily of TA-65 (an Astragalus membranaceus extract) versus placebo for 12 weeks with a 3-week washout in 40 patients with metabolic syndrome. Compared to placebo, TA-65 treatment led to significantly higher HDL-C and lower BMI, waist circumference, LDL/HDL ratio, and plasma TNF-alpha (p < 0.05 for all). Changes in HDL-C between periods were negatively correlated with changes in CRP (r = -0.511, p < 0.01), ALT (r = -0.61, p < 0.001), and TNF-alpha (r = -0.550, p < 0.001).
- Study type
- Double-blind, randomized crossover trial
- Who was studied
- 40 patients with metabolic syndrome
- What was measured
- Dyslipidemias, anthropometric markers, inflammatory cytokines, liver enzymes, glucose, and oxidative stress markers
THE PAPER
TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome.
Fernandez ML, Thomas MS, Lemos BS, DiMarco DM, Missimer A, Melough M, Chun OK, Murillo AG, Alyousef HM, Medina-Vera I. Curr Pharm Des, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.